Skip to content
approvedHormone Regulation

Desmopressin

Also known as: DDAVP, Stimate, Minirin, Nocdurna, Noctiva, 1-Deamino-8-D-Arginine Vasopressin

Desmopressin (DDAVP) is a synthetic analog of vasopressin (antidiuretic hormone) with two key modifications — deamination at position 1 and D-arginine substitution at position 8 — that dramatically increase its antidiuretic potency while eliminating the vasopressor effects. FDA-approved for central diabetes insipidus, primary nocturnal enuresis (bedwetting), nocturia, and as a hemostatic agent for type 1 von Willebrand disease and mild hemophilia A, it is one of the most versatile peptide drugs in clinical medicine. Available as oral tablets, nasal spray, sublingual melt, and injectable formulations.

3 cited references·5 researched benefits

Quick Answer

Desmopressin (DDAVP) is a synthetic vasopressin analog with enhanced antidiuretic activity and no vasopressor effect. FDA-approved for central diabetes insipidus, bedwetting, nocturia, and bleeding in von Willebrand disease and mild hemophilia A. It works through V2 receptor activation, promoting water reabsorption in the kidneys and releasing stored von Willebrand factor and factor VIII from endothelial cells. Available as tablets, nasal spray, and injection.

Key Facts

Mechanism
Desmopressin is a highly selective V2 receptor agonist with minimal V1a receptor activity, explaining its potent antidiuretic effect without significant vasoconstriction. At the renal collecting duct, V2 receptor activation triggers the cAMP/PKA signaling cascade that promotes translocation of aquaporin-2 (AQP2) water channels to the apical membrane, dramatically increasing water permeability and reabsorption — concentrating urine and reducing urine output. Its antidiuretic potency is 10-12 times greater than native vasopressin. For hemostatic applications, V2 receptor activation on vascular endothelial cells triggers exocytosis of Weibel-Palade bodies, releasing stored von Willebrand factor (vWF) and factor VIII:C into the circulation, typically raising levels 3-5 fold within 30-60 minutes. Desmopressin also promotes platelet adhesion through increased vWF-mediated GPIb binding.
Research Status
approved
Half-Life
~2-3 hours (plasma); antidiuretic effect lasts 6-14 hours
Molecular Formula
C₄₆H₆₄N₁₄O₁₂S₂
Primary Use
Hormone Regulation
Table of Contents

Benefits

  • Definitive treatment for central diabetes insipidus — replaces deficient ADH and normalizes urine output and thirst in >95% of patientsstrong
  • Reduces bedwetting episodes in primary nocturnal enuresis — effective in 60-70% of children, with 25-30% achieving full drynessstrong
  • Hemostatic agent for type 1 von Willebrand disease — raises vWF and factor VIII levels 3-5 fold, controlling bleeding without blood productsstrong
  • Treats mild hemophilia A (factor VIII >5%) — transiently raises factor VIII levels sufficient for minor surgical procedures and bleeding episodesstrong
  • Reduces nocturia episodes in adults — Nocdurna/Noctiva sublingual formulations specifically approved for nocturia due to nocturnal polyuriastrong

Dosage Protocols

RouteDosage RangeFrequencyNotes
Intranasal spray (diabetes insipidus)10-40 mcg1-3 times daily, divided dosesDDAVP nasal spray delivers 10 mcg per spray. Adjust dose to control thirst and urine output. Fluid intake must be restricted to prevent hyponatremia.
Oral tablet (diabetes insipidus/nocturnal enuresis)0.1-0.4 mg2-3 times daily (DI); at bedtime (enuresis)Oral bioavailability is ~5% but dose is adjusted accordingly. For enuresis, start 0.2 mg at bedtime and titrate to 0.6 mg. Restrict evening fluids.
Sublingual melt (Nocdurna)27.7 mcg (women) or 55.3 mcg (men)Once daily, 1 hour before bedtimeSpecifically approved for nocturia due to nocturnal polyuria. Gender-specific dosing. Contraindicated in patients at risk for hyponatremia; monitor sodium at 1 week and 1 month.
Intravenous or subcutaneous (hemostatic)0.3 mcg/kgSingle dose; may repeat once at 12-24 hoursFor von Willebrand disease type 1 or mild hemophilia A. Infuse IV over 15-30 minutes. Check vWF/factor VIII response with test dose before relying on for surgery. Tachyphylaxis limits repeated dosing.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Hyponatremia — the most serious risk; water retention without adequate fluid restriction can cause dilutional hyponatremia, seizures, and cerebral edema, especially in children and elderlyserious
  • Headache — the most common adverse effect, reported in 10-25% of patients across formulationscommon
  • Nausea and abdominal pain — gastrointestinal complaints in 5-15% of patients, particularly with oral formulationscommon
  • Nasal congestion, rhinitis, and epistaxis — with intranasal formulations, occurring in 3-10% of patientscommon
  • Facial flushing — transient vasodilation particularly with IV desmopressin, seen in 5-10% of patientscommon
  • Tachyphylaxis — reduced hemostatic response with repeated doses over 24-48 hours due to depletion of vWF/factor VIII storesrare

Frequently Asked Questions

How dangerous is hyponatremia from desmopressin?
Hyponatremia is the most serious risk of desmopressin therapy and can be life-threatening if unrecognized. Desmopressin causes the kidneys to retain water; if fluid intake is not restricted, serum sodium drops. Symptoms range from headache and nausea (mild, Na 125-130) to confusion, seizures, and fatal cerebral edema (severe, Na <120). Children using desmopressin for bedwetting are particularly at risk during sleepovers or parties where fluid intake may increase. Current guidelines recommend restricting fluids from 1 hour before to 8 hours after dosing and monitoring serum sodium at baseline, 1 week, and periodically thereafter.
Can desmopressin be used for all types of von Willebrand disease?
Desmopressin is effective primarily for type 1 von Willebrand disease, where vWF is quantitatively reduced but qualitatively normal — it releases stored vWF from endothelial cells. It is generally ineffective or contraindicated in type 3 vWD (complete absence of vWF, so there are no stores to release). In type 2 vWD, use varies by subtype: type 2A may show partial response, type 2B is typically contraindicated (can worsen thrombocytopenia by releasing dysfunctional vWF that binds platelets), and type 2M/2N responses vary. A therapeutic trial (DDAVP challenge test) is recommended before relying on desmopressin for surgical hemostasis.
What is the difference between DDAVP and vasopressin?
Desmopressin (DDAVP) and vasopressin (ADH) both act on vasopressin receptors but with very different pharmacology. Vasopressin activates both V1a (vasoconstriction) and V2 (antidiuresis) receptors and has a half-life of 10-20 minutes. Desmopressin is 10-12 times more potent at V2 receptors but has almost no V1a activity, so it concentrates urine without raising blood pressure. Its half-life is 2-3 hours. Vasopressin is used for vasodilatory shock and cardiac arrest (where vasoconstriction is desired), while desmopressin is used for diabetes insipidus, enuresis, and hemostasis (where antidiuresis and vWF release are desired without cardiovascular effects).
At what age can children start desmopressin for bedwetting?
Desmopressin is generally recommended for primary nocturnal enuresis starting at age 6, after behavioral interventions and bedwetting alarms have been tried. Most guidelines recommend trying a bedwetting alarm first as it has higher long-term cure rates, but desmopressin is preferred for rapid symptomatic relief (e.g., for camp or sleepovers). Response rates are about 60-70%, with full dryness in 25-30% of children. Treatment is typically continued for 3 months, then a 1-week withdrawal trial is attempted. Relapse after stopping is common (50-60%), and many children require intermittent or extended courses.

References

  1. 1
    Desmopressin: a review of its pharmacological properties and clinical use in the management of diabetes insipidus(1987)PubMed ↗
  2. 2
    Desmopressin for the treatment of nocturnal enuresis in children: a systematic review and meta-analysis(2007)PubMed ↗
  3. 3
    Desmopressin in von Willebrand disease: efficacy, safety and clinical utility(2012)PubMed ↗

Latest Research

Last updated: 2026-02-19